# A Study YL201 in Patients With Selected Advanced Solid Tumors

> **NCT06057922** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MediLink Therapeutics (Suzhou) Co., Ltd.** · enrollment: 990 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** YL201 for Injection

## Key facts

- **NCT ID:** NCT06057922
- **Lead sponsor:** MediLink Therapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-22
- **Primary completion:** 2026-10
- **Final completion:** 2028-10
- **Target enrollment:** 990 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06057922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06057922, "A Study YL201 in Patients With Selected Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06057922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*